Diazoxide

Evidence Level: L5

Predicted Indications: 9

Diazoxide

Pharmacist Assessment Report

Diazoxide: From Hyperinsulinemic Hypoglycemia to Hypotrichosis Simplex of the Scalp

One-Sentence Summary

Diazoxide is a potassium channel opener, originally used to treat hyperinsulinemic hypoglycemia, including insulinoma and congenital hyperinsulinism. The TxGNN model predicts it may be effective for alopecia (the top-ranked prediction is hypotrichosis simplex of the scalp), but there are currently no registered clinical trials and only 6 publications for alopecia, most of them reviews, case reports, or animal studies. Evidence is therefore limited to preclinical and mechanistic support.

Quick Overview

Item	Content
Original Indication	Hyperinsulinemic hypoglycemia (including pancreatic insulinoma and congenital hyperinsulinism)
Predicted New Indication	Hypotrichosis simplex of the scalp (rank 1); alopecia (rank 4) has the most relevant supporting literature
TxGNN Prediction Score	0.9996 (hypotrichosis simplex of the scalp); 0.9991 (alopecia)
Evidence Level	L5 (hypotrichosis simplex of the scalp); L4 (alopecia)
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the data compiled for this report. Based on known information, diazoxide opens ATP-sensitive potassium (KATP) channels. In the pancreas, this suppresses insulin release, which explains its use in hyperinsulinemic hypoglycemia. The same channel-opening action is the proposed reason for its well-known side effect of excess hair growth (hypertrichosis).

This is the basis for the hair-related predictions. Minoxidil, a related vasodilator that also acts through KATP channels, is established as a hair-growth treatment. Topical diazoxide produced hair regrowth in the bald scalps of macaques, an animal model of androgenetic alopecia. The link is therefore plausible for hair-loss conditions in which stimulating follicle growth could help.

The link is much weaker for other predicted conditions:

Hypotrichosis simplex and congenital hypotrichosis milia: These are genetic conditions, so stimulating growth may not address the underlying defect, and no supporting data exist.
Diffuse alopecia areata: This is autoimmune, and KATP-driven growth does not address the immune cause.
Hypertrichosis and Ambras type hypertrichosis: These involve excess hair. Diazoxide causes hypertrichosis, so these scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence of a therapeutic relationship. They should not be pursued.
Autosomal dominant hyperinsulinism due to Kir6.2 deficiency: This is close to the existing approved use, so it is closer to an on-label use than true repurposing. Efficacy depends on the variant, since dominant KCNJ11 variants are often unresponsive to diazoxide.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Literature for alopecia (rank 4):

PMID	Year	Type	Journal	Key Findings
2085505	1990	Animal study (primate)	J Dermatol Sci	Topical diazoxide applied to the bald frontal scalp of stumptailed macaques, taking advantage of its hypertrichotic effect; systemic side effects were also monitored
8326148	1993	Review	J Invest Dermatol	Topical minoxidil and diazoxide induced significant hair regrowth in bald macaque scalps (androgenetic alopecia model)
8018303	1994	Review	Drug Saf	Review of drug-induced hair loss and hair growth, including incidence, management and avoidance
37042338	2023	Case report	Pediatr Dermatol	Child with generalized hypertrichosis from topical minoxidil exposure; diazoxide listed among causative drugs (indirect evidence)
20682429	2010	Review	Vet Clin North Am Exot Anim Pract	Medical management of insulinomas in ferrets, including diazoxide (not related to alopecia)
4340017	1972	Case series	Arch Dis Child	Fetal exposure to diazoxide in four infants (not related to alopecia)

Literature for hypertrichosis (rank 7) mainly documents hypertrichosis as an adverse effect of diazoxide, for example a neonatal case (36726424, 2023), a Japanese post-marketing survey of 384 children in which hypertrichosis was the most common adverse reaction at 8.6% (30083030, 2018), and real-world congenital hyperinsulinism data (40917359, 2025). These papers do not support a therapeutic use.

No literature was available for the other predicted conditions.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
00503347	PROGLYCEM	Not specified	Not specified

Safety Considerations

Contraindication-related diseases (from the knowledge graph, not label text): Diazoxide is flagged as contraindicated or to be used with caution in conditions including:

Metabolic: diabetes mellitus, hyperglycemia, diabetic ketoacidosis, gout, hyperuricemia, potassium deficiency
Cardiovascular: congestive heart failure, coronary artery disease, cerebrovascular disorder, orthostatic hypotension, postural orthostatic tachycardia syndrome, multiple system atrophy
Renal and hepatic: kidney disease, kidney failure, uremia, liver disease, gallbladder disease, pyoureter

Drug Interactions: 100 interactions were identified. The 20 listed are all moderate severity, mainly with other blood-sugar-lowering drugs and corticosteroids:

Antidiabetic agents: acarbose, alogliptin, albiglutide, dulaglutide, metformin, pioglitazone, chlorpropamide, acetohexamide, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin
Corticosteroids: hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone
Others: bupropion, morphine, dronabinol

Adverse effects reported in the literature: Hypertrichosis, fluid retention, cardiac failure, hyperglycemia, acute renal failure, and necrotizing enterocolitis in neonates. Systemic use carries substantial risk, so any hair-loss development would likely need a topical route.

Please refer to the package insert for the official warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale:

The predictions rest on model scores alone, with no clinical trials. For alopecia, the only support is animal data and mechanistic similarity to minoxidil. Several predictions (hypertrichosis, Ambras type hypertrichosis) reflect a side-effect association rather than a therapeutic one. Alopecia may be treated as a research question rather than a development candidate.

To proceed, the following is needed:

Detailed mechanism-of-action data
Package insert warnings and contraindications from Health Canada, which are needed before safety screening
Human data on topical diazoxide for androgenetic alopecia, including dose, formulation, and local and systemic safety
Assessment of a topical formulation, since systemic diazoxide has significant adverse effects
Confirmation of the approved indication and dosage form for the Canadian product (PROGLYCEM)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.